Literature DB >> 30719430

Failing to Make Ends Meet: The Broad Clinical Spectrum of DNA Ligase IV Deficiency. Case Series and Review of the Literature.

Aidé Tamara Staines Boone1, Ivan K Chinn2,3, Carmen Alaez-Versón4, Marco A Yamazaki-Nakashimada5, Karol Carrillo-Sánchez4, María de la Luz Hortensia García-Cruz6, M Cecilia Poli2,7, M Edith González Serrano8, Edgar A Medina Torres8, David Muzquiz Zermeño1, Lisa R Forbes2,9, Francisco J Espinosa-Rosales8,10, Sara E Espinosa-Padilla8, Jordan S Orange2,9, Saul Oswaldo Lugo Reyes8.   

Abstract

DNA repair defects are inborn errors of immunity that result in increased apoptosis and oncogenesis. DNA Ligase 4-deficient patients suffer from a wide range of clinical manifestations since early in life, including: microcephaly, dysmorphic facial features, growth failure, developmental delay, mental retardation; hip dysplasia, and other skeletal malformations; as well as a severe combined immunodeficiency, radiosensitivity, and progressive bone marrow failure; or, they may present later in life with hematological neoplasias that respond catastrophically to chemo- and radiotherapy; or, they could be asymptomatic. We describe the clinical, laboratory, and genetic features of five Mexican patients with LIG4 deficiency, together with a review of 36 other patients available in PubMed Medline. Four out of five of our patients are dead from lymphoma or bone marrow failure, with severe infection and massive bleeding; the fifth patient is asymptomatic despite a persistent CD4+ lymphopenia. Most patients reported in the literature are microcephalic females with growth failure, sinopulmonary infections, hypogammaglobulinemia, very low B-cells, and radiosensitivity; while bone marrow failure and malignancy may develop at a later age. Dysmorphic facial features, congenital hip dysplasia, chronic liver disease, gradual pancytopenia, lymphoma or leukemia, thrombocytopenia, and gastrointestinal bleeding have been reported as well. Most mutations are compound heterozygous, and all of them are hypomorphic, with two common truncating mutations accounting for the majority of patients. Stem-cell transplantation after reduced intensity conditioning regimes may be curative.

Entities:  

Keywords:  DNA repair defects; case series; clinical spectrum; inborn error of immunity; ligase IV deficiency; primary immunodeficiency

Year:  2019        PMID: 30719430      PMCID: PMC6348249          DOI: 10.3389/fped.2018.00426

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


Introduction

Inborn errors of immunity are a group of over 350 individually rare congenital diseases that result from mutations in one or more genes coding for proteins of the immune system. DNA repair defects result from mutations in any of several genes coding for proteins in a complex nuclear machinery that detect and fix double strand DNA breaks. Every cell in our body is exposed to 10 to 50 DNA double strand breaks per day, from intracellular mechanisms (meiosis, isotype class switch, gene recombination) and extracellular insults (free radicals, ionizing radiation, drugs) (1). In lymphocytes, a crucial process is the generation of diversity in T-cell receptors and immunoglobulins through V(D)J somatic recombination, which starts with the introduction of double strand breaks in the genes by RAG1 and RAG2 (2). Defects in the DNA repair machinery proteins (ATM, RAD50, NHEJ1, Artemis, NBN, SBDS, LIG4, MRE11, POLE) result in increased apoptosis, and oncogenesis. Most patients with DNA repair defects share a syndrome of neurologic deficits, combined (T and B-cell) immunodeficiency, bone marrow failure and/or hematologic neoplasia (3). DNA Ligase IV is a 911-aminoacid protein, a nuclear enzyme with a DNA binding domain and two BRCT motifs, involved in double strand DNA repair through the non-homologous end-joining (NHEJ) pathway, the major repair mechanism in mammalian cells, which consists of at least 5 proteins. Specifically, the LIG4/XRCC4 complex oversees the final ligation step of the process (making ends of the repaired strands meet). Knockout models of the gene LIG4, located in human chromosome 13 and consisting of a single long exon, are lethal to mouse embryos because of massive neuronal apoptosis (4); all known human mutations are thus hypomorphic and result in a wide clinical spectrum, ranging from normal to severely compromised immune system with microcephaly, growth failure, facial dysmorphism, mental retardation, hypogonadism, progressive bone marrow failure, and leukemia or lymphoma. The physiopathology at a cellular level includes mutagenesis, apoptosis and oncogenesis, despite some residual function of LIG4, and despite a redundant DNA repair machinery. The resulting immune defect might be a radiosensitive T-B-NK+ severe-combined immunodeficiency. Even with a clinically normal phenotype, chances are that lymphocytes will have a restricted receptor repertoire, and that hematopoietic cells be susceptible to ionizing radiation and other insults, with cumulative DNA damage leading to bone marrow failure and hematologic malignancies (5). Here, we describe five cases of DNA Ligase 4 deficiency (MIM phenotype number #606593) in two unrelated families from Mexico, whose clinical presentations ranged from lymphoma and early death, to mild disease. We reviewed the literature to further document the varying clinical presentations. Written informed consent was obtained from the parents of all patients, for the publication of this case series, and any potentially identifying information, including face pictures and family trees.

Case Reports

Family A

A one-year-old boy from Northern Mexico was referred to UMAE-25 to rule out primary immunodeficiency. The third of four siblings, he was born at term to non-consanguineous parents. An elder brother had died of Non-Hodgkin lymphoma of the brain at age 18 months old. He received BCG vaccination at birth, in 2005. At age 4 months he was hospitalized for viral encephalitis, and at 12 months for pneumonia and sepsis, with positive Cytomegalovirus (CMV) viral load (2,020 copies/ml); he suffered recurrent upper respiratory, gastrointestinal, and urinary infections; he developed oral candidiasis and a perianal ulcer caused by Pseudomonas spp; laboratory workup showed anemia (Hb 8.13 g/dL) and thrombocytopenia (80,000 per microliter), with normal leukocyte numbers and serum immunoglobulin levels: IgG 760 mg/dL, IgM 49 mg/dL, IgA 83 mg/dL; flow cytometry of lymphocyte subsets reported low CD4+ (110 cells/μl) and CD8+ (307 cells/μl) T-cells, with 1982 B-cells (43%), and 130 NK cells (9%); HIV infection was ruled out. A bone marrow aspirate showed myeloid maturation arrest with dysplastic forms. He was admitted with neurologic decay, fever, and systemic inflammation shortly before his death. The autopsy confirmed a diffuse large B-cell Non-Hodgkin lymphoma. Immunohistochemical staining for Epstein-Barr virus (EBV) was not available. A second sister died at age 9 months of lung lymphoma. She started at 4 months old, with three episodes of pneumonia and one of sepsis; she suffered from milk protein allergy, vulvovaginal candidiasis, and diaper area dermatitis; her laboratory workup found: transient peripheral lymphopenia, low T-cells subsets (CD4+ 8 to 403 cells/mm3, CD8+ 6 to 232/mm3) with normal B and NK cells; normal serum immunoglobulin levels (IgG 853mg/dL, IgM 41, IgA 64 mg/dL, IgE < 18 IU/ml); positive CMV viral load, Acinetobacter baumanii cultured from blood, Enterococcus faecium from urine, and Enterobacter aerogenes from bronchial aspirate. Cystic fibrosis, HIV infection, tuberculosis, and gastroesophageal reflux disease were ruled out; a nitroblue tetrazolium (NBT) reduction assay was normal at 81%. The chest X-ray showed a paravertebral mediastinal mass; a chest computed tomography (CT) confirmed a well-delimited, right retrocardiac rounded mass shortly before her death. She deteriorated abruptly with metabolic acidosis, progressive respiratory distress and heart failure; she was admitted to the intensive care unit and received mechanical ventilation support, broad-spectrum antibiotic, milrinone, and cyclophosphamide, without improvement. The autopsy confirmed a diffuse large B-cell lymphoma; EBV staining was not performed. Our patient, the third sibling, received the BCG vaccine at birth, without complications. Before 1 year of age he was treated for uncomplicated pharyngitis and avascular necrosis of the femoral head (Legg-Calvé-Perthes disease). Given his family history, he was started on oral trimethoprim/sulfamethoxazole (TMP/SMZ) and sent to our hospital for evaluation. Other than an initially positive CMV viral load (440 copies/ml, age 1 year, treated with ganciclovir for 90 days), his first laboratory workup was unremarkable. A CT scan from head to abdomen was normal. Serum immunoglobulin levels and absolute lymphocyte counts were normal at age 1, 4, and 7 years old. In contrast, the CD4+ T-cell subset count has remained steadily low (163–657 cells/mm3, or 7–23%). The Mantoux tuberculin skin test was reactive at 11 mm of induration, at age 7 months. However, CFSE lymphocyte proliferation assay was low at age 9 months, and absent 3 years later, under: PMA/ionomycin, phytohemagglutinin, concanavalin, and anti-CD3/CD28 stimuli (Figure 3).
Figure 3

Carboxyfluorescein succinimidyl ester lymphoproliferation assay, plot (upper panel), and indexes (lower panel).

Whole-exome sequencing, performed at Texas Children's Hospital, revealed a compound heterozygous pathogenic variant (missense and small 5bp deletion) in LIG4: c.833G>A (p.R278H)/c.1271_1275delAAAGA (p.K424RfsX20). The p.K424R variant encodes a truncated protein missing 482 aminoacids; its frequency is lower than 0.03% for all populations according to ExAc (exac.broadinstitute.org). The p.R278H variant is predicted to be deleterious by all: DANN, GERP, dbNSFP, FATHMM, LRT, MetaLR, MetaSVM, MutationAssessor, MutationTaster, and PROVEAN in silico predictors. Both variants have been previously reported in patients with LIG4 deficiency and predicted to be deleterious by both SIFT and PolyPhen (transcript NM_206937.1, LIG4base, www.ensembl.org). In time, the patient, now 6 years old, developed obesity with normal stature and head circumference (see Figure 1), and no other manifestation. A younger brother, born in 2017, is also asymptomatic, in apparent good health (Figure 2).
Figure 1

(A) Short stature with overweight in normocephalic school-age boy. Contrast with (B,C) Facial dysmorphisms seen in two twin sisters with LIG4 deficiency. Note prominent middle third of the face, long nose, micrognathia, long ears, jaundice, protruding tongue. (Face photos published with permission from their mothers).

Figure 2

Family trees. In Family A, the elder siblings of the proband died young of lymphoma. The proband has a history of avascular necrosis of the femoral head, short stature and isolated CD4+ deficiency; his younger brother is asymptomatic. In Family B, teenage twin sisters died after a long history of recurrent infections, chronic liver disease, and progressive bone marrow failure (The pedigrees were built at pedigree.progenygenetics.com; they are included after written informed consent from the mothers).

(A) Short stature with overweight in normocephalic school-age boy. Contrast with (B,C) Facial dysmorphisms seen in two twin sisters with LIG4 deficiency. Note prominent middle third of the face, long nose, micrognathia, long ears, jaundice, protruding tongue. (Face photos published with permission from their mothers). Family trees. In Family A, the elder siblings of the proband died young of lymphoma. The proband has a history of avascular necrosis of the femoral head, short stature and isolated CD4+ deficiency; his younger brother is asymptomatic. In Family B, teenage twin sisters died after a long history of recurrent infections, chronic liver disease, and progressive bone marrow failure (The pedigrees were built at pedigree.progenygenetics.com; they are included after written informed consent from the mothers). Carboxyfluorescein succinimidyl ester lymphoproliferation assay, plot (upper panel), and indexes (lower panel).

Family B

Two teenage girl twins from Western Mexico were referred to INER for recurrent respiratory infections. They had a history of microcephaly and facial dysmorphism, with growth and psychomotor delay. Born pre-term (at 32 weeks of gestation) to non-consanguineous parents, the patients had three healthy elder siblings, and a pet dog. During their first months of life, they suffered from 3 to 4 pneumoniae, gastroenteritis, and urinary tract infections. By 13 years of life, when they were referred to the National Institute of Pediatrics, they had developed moderate generalized jaundice with hepatosplenomegaly. On physical examination, short stature (below percentile 10), low weight, mild to moderate mental retardation and speech delay were noted, with microcephaly below p3, a prominent mid-face with long nose, and micrognathia with a protruding tongue (see Figure 1). They had primary amenorrhea with absent secondary sexual features. A chest CT documented diffuse bilateral bronchiectasis; abdominal ultrasound and a barium swallow revealed portal hypertension with esophageal varices. Laboratory workup showed persistent mild leukopenia with lymphopenia. Since around age twelve, they developed progressive pancytopenia: Hb 8g/dL, lymphocytes 210–300/mm3, less than 500 neutrophils, and 120,000 platelets; as well as elevated liver enzymes: increased conjugated bilirubin, ALT, AST, GGT, alkaline phosphatase, high ferritin (over 600 ng/ml), low fibrinogen (100 mg/dL), and high triglycerides (300 mg/dl). All serum immunoglobulins and lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, CD16/56+) were also low: IgG 105–169 mg/dL, IgM 8.96–26.6 mg/dL, IgA < 6.67 mg/dL, IgE 1.1–1.5 IU/mL. A bone marrow aspirate reported medullary aplasia. Cellular radiosensitivity (radiomimetic assay) was negative to bleomycin; serologic tests for HepA, HepB, HepC, CMV, and EBV came back negative. Liver biopsy reported portal fibrosis with perivascular cell infiltration, suggestive of obstructive cirrhosis. A provisional diagnosis of Nijmegen breakage syndrome (NBS) with bone marrow failure and sclerosing cholangitis was given. They continued treatment with prophylactic antibiotics and monthly intravenous gammaglobulin (IVIG), as well as ursodeoxycholic acid, molgramostin (GM-CSF), and oral transfer factor (leukocyte dialysate). They died 2 years apart at ages 14 and 16, at their hometown hospital, one twin of sudden massive gastrointestinal bleeding, and the other of sepsis and multiorgan failure (with pneumonia, anuria, and a distended abdomen). No autopsy was performed. NBN was amplified and sequenced in Berlin with no mutations found. Years later, a targeted exome panel (Illumina TruSight) performed at INMEGEN in Mexico, revealed a compound heterozygous mutation in LIG4, consisting of the same 5 base-pair deletion as that of family A (c.1271_1275delAAAGA) in allele 1 (p. K424RfsX20), and a missense point mutation (c.745A>G) in allele 2 (p.M249V); both previously reported in patients with LIG4 deficiency (transcript NM_206937.1; LIG4base, www.ensembl.org), and predicted to be deleterious/probably damaging by both SIFT and PolyPhen. The p.M249V variant is absent from population databases such as gnomAD exomes; it is also predicted to be deleterious/probably damaging by all: DANN, GERP, dbNSFP, FATHMM, LRT, MetaLR, MetaSVM, MutationAssessor, MutationTaster, and PROVEAN in silico predictors.

Review of the Literature

The first patient with LIG4 deficiency, a 14-year-old teenage boy with acute lymphoblastic leukemia who died 8 months after receiving prophylactic cranial radiotherapy, was characterized clinically in 1990 (6), and genetically in 1999 (7). Tables 1–3 summarize the clinical, laboratorial and genetic findings of all published patients available in PubMed Medline (https://www.ncbi.nlm.nih.gov/pubmed/) as of August 2018. Clinical and immunological manifestations vary widely, even among siblings with the same mutation. Table 4 summarizes the prevalence of neurological, developmental, infectious, and hematological components of LIG4 deficiency. The degree of protein truncation (early, mid, and late) seems to correlate with clinical, hematological, and immunological severity (mild, moderate, and severe).
Table 1

Demographic and clinical features of published patients with LIG4 deficiency.

PatientOriginSexFamilyAge at dx (years)OnsetClinical featuresStatusReferences
1 (180BR)Turkish-cypriotMale14B-symptomsWeight loss, anorexia, lethargy, pallor, lymphadenopathy, hepatosplenomegaly: Acute lymphoblastic leukemiaDied 8 months after radiotherapy6, 7
2USAFem26Microcephaly and microsomy, lethargy and dizzinessSeckel syndrome. Cough, fever, pallor.Died of pneumonia 2 months after chemotherapy(8)
3 (411BR)GermanyMale9MicrocephalyDysmorphism, developmental delay and plantar warts.Died at age 23 of lymphoma(4, 9, 10)
4 (2303)USAMaleSibling to 230446MicrocephalyChronic skin conditions, photosensitivity, telangiectasia, sinusitisNR(9)
5 (2304)USAFemSibling to 230348MicrocephalyDysmorphism, growth failure, respiratory infections, psoriasisNR(9)
6 (99P0149)GermanyFemNon-consang.9MicrocephalyDysmorphism, dwarfism, mental delay, psoriasisAlive and well 5 years after RIC HSCT from HLA-identical brother(9, 11)
7 (3703)CanadaMaleFirst cousin died of brain tumor in early childhood4.75Acute leukemiaMicrocephaly, dysmorphism, developmental delay, hypogonadism, leukemiaDied shortly after chemotherapy(12)
8 (SC2)TurkishFemConsang., heterozygous1.5Respiratory infectionsRespiratory infections, candidiasis, chronic diarrhea, failure to thrive, feverDied after conditioning, possibly due to veno-occlusive disease.(13)
9 (P2)GermanFemSister to 100MicrocephalyAlive after HSCT(14)
10 (P1)GermanFemSister to 92Recurrent infectionsChronic diarrhea, recurrent infections, failure to thrive, autoimmune cytopeniaDied shortly after chemotherapy(14)
11 (P-1)MoroccoFemSister to 121.5Repeated infections since 3 months oldMicrocephaly, otitis, bronchiolitis, pneumonia and sepsisDied of EBV PTLD 50 days after HSCT(2)
12 (P-2)MoroccoFemSister to 110MicrocephalyDied of VOD 2 months after HSCT(2)
13JapanFem14Mouth tumor, feverMicrocephaly, short stature, polydactyly,Died after chemotherapy(15)
14CanadaFemNon-consang.0.1Omenn syndromeMicrocephaly, low weight, rash, hepatosplenomegaly, lymphadenopathy, diarrhea.Alive and well 3.5 y after full conditioning HSCT(16)
15TurkishFemConsang., sister to 1610Microcephaly, respiratory infectionsSinopulmonary recurrent infectionsAlive and well after 2 RIC HSCTs(8)
16TurkishMaleConsang., brother to 156EcchymosesLow weight, upper respiratory and urinary infectionsAlive(8)
17 (F10)NetherlandsMale0.25Microcephaly, dysmaturity, dysmorphismFeeding difficulties, diarrhea, failure to thrive, icterus, tubulopathy, erythemaDied at 6 months of sepsis, respiratory insufficiency and severe gastrointestinal bleeding(17, 18)
18USAFem34Dubowitz syndromeRectorrhagiaDied of metastatic anal cancer(18, 19)
19 (F1.1)CanadaFemSister to 2017.5MicrocephalySmall cerebral aneurysm, primary ovarian failureAlive(18)
20 (F1.2)CanadaFemSister to 1911.75MicrocephalyAtrial-ventricular septal defect, atrofphic kidney, rib hypoplasia, fusion of carpal bones, copper beaten skull, platybasia, abnormal C1 vertebrae, primary ovarian failure.Alive(18)
21 (F2)USAFem7.8Microcephaly, malformationsAnal atresia with rectovaginal fistula, esotropia.Alive(18)
22 (F3)AustraliaFem2.1Microcephaly, hip dysplasiaUnilateral congenital hip dysplasia, cutis marmorata.Alive. BMT(18)
23 (F4)UKFem2.5Microcephaly, psoriasisPsoriasisAlive(18)
24 (F5)USAMale2Microcephaly, hip dysplasiaUnilateral congenital hip dysplasia.Alive(18)
25 (F6)GermanyFem2Microcephaly, hip dysplasiaCongenital hip dysplasia, 2/3 toe syndactyly, excessive vomitingAlive(18)
26 (F7)USAFem3.67Microcephaly, growth failureNoneAlive(18)
27 (F8)UKFem1.75Microcephaly, growth failureNoneAlive(18)
28 (F9)TurkeyMale5.5Microcephaly, hypopigmentationHypopigmentation, hypermobile knees, single palmar crease, 2/3 toe syndactyly, sandal gapAlive(18)
29 (P2)North AmericaFemSibling to P1 and P313Recurrent pneumonias and sinusitisRecurrent respiratory infections, microcephaly, short stature.Alive(5)
30(P1)North AmericaMaleSibling to P2 and P3NANAOne walking pneumoniaAlive(5)
31 (P3)North AmericaFemSibling to P1 and P2NANAAsymptomaticAlive(5)
32BelarusFem2StomatitisUlcerated stomatitis, encephalitis, lung and brain lymphoma.Died of lymphoma(20)
33 (C1)African/Asian descentFem7Dysmorphic features, developmental delayRespiratory infections, pancytopeniaAlive and well after HSCT(21)
34 (C2)MoroccoMaleElder sister died at 18 mo. with pancytopenia9Chronic diarrheaChronic diarrhea, recurrent respiratory infections, hemorrhagic syndromeDied of aplasia at age 10(21)
35SyriaFemConsang.7Dysmorphic features and developmental delayRecurrent sinopulmonary infections, urosepsis, urofacial syndromeDied of pneumonia(22)
36ItalyMale6Complicated pneumoniaRecurrent upper respiratory infections since age 1, dysgammaglobulinemiaAlive(23)
37 LRLMexicoFemTwo brothers. 3 first cousins died of infections before age 20.75Pneumonia at 4 monthsDied of lymphomaThis report
38 PRLMexicoMaleTwo siblings1.5Pneumonia at 12 monthsDied of lymphomaThis report
39 FRLMexicoMaleTwo siblings1Pharyngoamigdal. at 2 monthsAvascular necrosis of femoral head, overweight.Alive and wellThis report
40 MGPMexicoFemTwin sister10Recurrent respiratory infectionsMicrocephaly, dysmorphism, developmental delay, recurrent infections, jaundiceDiedThis report
41 BGPMexicoFemTwin sister10Recurrent respiratory infectionsMicrocephaly, dysmorphism, developmental delay, recurrent infections, jaundiceDiedThis report

NR, Not reported.

Table 3

Immunological and genetic features of published patients with LIG4 deficiency.

PatGerms (isolates)Serum immunoglobulinsOther (comment)Mutation typeAllele 1Allele 2References
1 (180BR)NRNot reportedProphylactic cranial radiation: ulcers, lethargy, tetraparesishom, missc. 833 G>A (p. R278H)c. 833 G>A (p. R278H)(6, 7)
2NRNot reportedChromosomal abberrations. Chemotherapy: severe toxicityNRNDND(8)
3 (411BR)NRLowMicrocephaly at birth, not evident at age 9. Null B-cells, low T. T-B-NK+ CIDhom, miss, (+2 polymorphisms)c. 833 G>A/8 C>T/26 C>T (p. R278H/A3V/T9I)c. 833 G>A/8 C>T/26 C>T (p. R278H/A3V/T9I)(4, 9, 10)
4 (2303)NRNot reportedHypothyroidism, type 2 diabetes, hypogonadismcomp het, nonsc. 1738 C>T (p.R580X)c. 2440C>T (p.R814X)(9)
5 (2304)NRNot reportedHypothyroidism, amenorrheacomp het, nonsc. 1738 C>T (p.R580X)c. 2440C>T (p.R814X)(9)
6 (99P0149)NRAll normalMultiple psoriasiform erythrodermic, squamous skin patches, atypical bone maturation, low CD3 and CD19comp het, miss/nonsc. 1406 G>A (p.G469E)c. 2440C>T (p.R814X)(9, 11)
7 (3703)NRNot reportedLow birth weight, criptorchidism, hypogonadism, clinodactylyhom, nonsc.2440C>T (p.R814X)c. 2440C>T (p.R814X)(12)
8 (SC2)CandidaLow IgG, IgA and IgMT-B-NK+ SCID, reduced lymphoproliferation (PHA, aCD3)hom, small delg.5333_5335delCAA (p. Q433del)g.5333_5335delCAA (p. Q433del)(13)
9 (P2)NoLow IgM, absent IgAT-B-NK+ SCID, isohemagglutinins presentcomp het, miss/nonsc.1118A>T (p. H282L)c.1544_1548delAAAGA (p.D423fs442X)(14)
10 (P1)S. pneumoniae, HHV6, Norwalk, EBV, AspergillusHigh IgG and IgM, normal IgAT-B-NK+ SCID, small thymus, autoimmune thrombocytopenia, no tetanus, diphteria or pneumococcus titerscomp het, miss/nonsc.1118A>T (p. H282L)c.1544_1548delAAAGA (p.D423fs442X)(14)
11 (P-1)S. pneumoniaeAbsent IgA, Low IgG and IgMT-B-NK+ SCID, reduced lymphoproliferationcomp het, miss/small delc.1544_1548del5bp (p.K424fs20X)c.1112A>G (p.Q280R)(2)
12 (P-2)NoLow IgM, absent IgA (maternal IgG)T-B-NK+ SCID, normal lymphoproliferationcomp het, miss/small delc.1544_1548del5bp (p.K424fs20X)c.1112A>G (p.Q280R)(2)
13Aspergillosis after neutropeniaLow IgM and IgGT-B-NK+ CIDcomp het, miss/small delc.745A>G (p.M249V)c.1270_1274del5bp (p.K424fs20X)(15)
14EBV after HSCTLow IgM and IgALow TRECs, B cells, lymphoproliferation, GVHDcomp het, miss/small delc.845A>T(p.H282L);c.26C>T (SNP)c.1747_1751del5bp (p.R581fsX)(16)
15NRLow IgMSpontaneous chromosomal breakages increased, normal bone marrow cellularityhom, small delc.1762delAAG (p.K588del)c.1762delAAG (p.K588del)(8)
16Low IgG and IgMInguinal hernia, spontaneous chromosomal breakage, normal BM cellularityhom, small delc.1762delAAG (p.K588del)c.1762delAAG (p.K588del)(8)
17 (F10)P aeruginosa, E faecalis, P jiroveci, rhinovirus, norovirus, astrovirus, C difficile, CandidaLow IgG and B-cellsPolydactyly, dysplastic kidneys, corpus callosum dysgenesia, very low B-cellscomp het, SN del trunc/truncc.613delT (p.S205LfsX29)c. 1904delA (p.Lys635ArgfsX10)(17, 18)
18NoNRRadiotherapy: desquamative skin injurycomp het, SN del trunc/nonsc.613delT (p.S205LfsX232)c.2440C>T (p.R814X)(18, 19)
19 (F1.1)NRLow IgGLow CD4+, null CD19+comp het, miss/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
20 (F1.2)NRLow IgGLow CD4+, null CD19+, very low naïve T cellscomp het, miss/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
21 (F2)NRNRNRcomp het, nonsc.2440C>T (p.R814X)c.2094C>G (p.Y698X)(18)
22 (F3)NRLow IgGLow CD3, CD8, very low CD19comp het, dup/nonsc.2440C>T (p.R814X)c.2386_2389dupATTG (p.A797DfsX3)(18)
23 (F4)NRLow IgGLow CD4+, very low CD19+comp het, nons/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
24 (F5)NRLow IgGLow CD3, CD4, CD8, very low CD19comp het, nons/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
25 (F6)NRLow IgGVery low CD19+comp het, nons/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
26 (F7)NRNRNRcomp het, nons/small delc.2440C>T (p.R814X)c.1512_1513delTC (p.R505CfsX12)(18)
27 (F8)NRLow IgGNRcomp het, nons/small delc.2440C>T (p.R814X)c.1246_1250dupGATGC (p.Leu418MetfsX3)(18)
28 (F9)NRNormalVery low CD19+comp het, nons/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(18)
29 (P2)NRPanhypogammaglobulinemiaLow CD3+, CD19+, naïve Tcomp het, miss/nonsc.2440C>T (p.R814X)c.1345A>C (p.K449Q)(5)
30(P1)NRNormal IgGLow CD19+, naïve T cellscomp het, miss/nonsc.2440C>T (p.R814X)c.1345A>C (p.K449Q)(5)
31 (P3)NoLow IgGLow CD3+, CD19+, naïve Tcomp het, miss/nonsc.2440C>T (p.R814X)c.1345A>C (p.K449Q)(5)
32EBVLow IgALow T cellscomp het, small del/missc.2736+3delCc.8C>T (p.A3V); c.26C>T(p.T9I)(20)
33 (C1)NRLow IgG and IgMcomp het, nons/small delc.2440C>T (p.R814X)c.1271_1275delAAAGA (p.K424RfsX20)(21)
34 (C2)HPVNRcomp het, miss/small delc.847A>G (p.K283E)c.1271_1275delAAAGA (p.K424RfsX20)(21)
35S. pneumoniae, H. influenzaeLow IgG2 and IgMLow CD4+, null CD19+. Urofacial syndrome with hom. LRIG2 mut.hom, missc.T1312C (p.Y438H)c.T1312C (p.Y438H)(22)
36NRAbsent IgA and IgM. Normal IgG, low IgG3Very low T and B cells. Poor response to vaccines. Bronchiectasiscomp het, miss/small delc. 833 G>A (p. R278H)c.1271_1275delAAAGA (p.K424RfsX20)(23)
37 LRLAcinetobacter baumanii, Enterococcus faecium, Enterobacter aerogenes, CMVAll normalLow T cellsNRNDNDThis report
38 PRLPseudomonas, CMVAll normalLow T cellsNRNDNDThis report
39 FRLNoAll normalLegg-Calvé-Perthes disease, right hip. Low CD4+, low lymphoproliferation.comp het, missc.1236T>A (p.N412K)c.32C>G (p.A11G)This report
40 MGPNRLow IgG, IgA and IgMPrimary amenorrhea, sclerosing cholangitiscomp het, small del/missc.1271_1275delAAAGA (p.K424RfsX20)c.745A>G (p.M249V)This report
41 BGPNRLow IgG, IgA and IgMPrimary amenorrhea, sclerosing cholangitisNRNDNDThis report

ND, Not done; NR, Not reported; NT, Not tested; IR, ionizing radiation; BLM, bleomycin; DEB, diepoxybutane; MITC, mitomycin C. All reported mutations are hypomorphic.

Table 4

Prevalence of clinical and laboratory features found in 41 LIG4 deficiency patients.

Female28/4168%
Microcephaly32/4080%
Dysmorphic facial features15/4137%
Growth failure28/4070%
Syndactyly/Polysindactyly4/4110%
Other malformations3/417%
Congenital hip dysplasia4/4110%
Infections (any)28/4168%
Sinopulmonary infections23/4156%
Skin conditions8/4120%
Warts2/415%
Hypogammaglobulinemia25/3083%
Very low CD19+ B-cells24/3080%
Malignancy10/4124%
Bone marrow failure17/3944%
Radiosensitivity24/2886%

(100% radiosensitivity with ionizing radiation).

Demographic and clinical features of published patients with LIG4 deficiency. NR, Not reported. Key features of published patients with LIG4 deficiency. NR, Not reported. Immunological and genetic features of published patients with LIG4 deficiency. ND, Not done; NR, Not reported; NT, Not tested; IR, ionizing radiation; BLM, bleomycin; DEB, diepoxybutane; MITC, mitomycin C. All reported mutations are hypomorphic. Prevalence of clinical and laboratory features found in 41 LIG4 deficiency patients. (100% radiosensitivity with ionizing radiation).

Discussion

We describe a series of five LIG4 deficiency patients with a wide spectrum of clinical manifestations, ranging from short stature and asymptomatic CD4+ lymphopenia, to liver failure with sudden massive bleeding. Although relatively small, this is one of the largest case series to date on the subject of LIG4 deficiency; the genetic diagnosis was confirmed in both families by whole-exome sequencing only, but we also reviewed the literature for all published patients to date (our job was aided by a recent review by Altmann and Gennery (1) comprising 28 LIG4 deficient patients up until 2016). Forty-one LIG4 deficiency patients have been described to date (In addition, Bluteau et al. recently found three cases of LIG4 deficiency among their cohort of bone marrow failure patients, although their features were not described in detail) (25). Their phenotypes are varied, with more clinical severity associated to early mutations and a truncated protein. The degree of severity is probably linked to the amount of residual function of the ligase, but confounded by the complex interactions and the intricate redundancy of the DNA repair defect machinery. To our knowledge, our patients from family B are the first to develop sclerosing cholangitis (SC) in the context of LIG4 deficiency. SC has been reported mainly in X-linked Hyper-IgM syndrome due to CD40L deficiency, but also in other forms of combined immunodeficiencies (26). This autoimmune complication is thought to result from the colonization of the bile ducts by Cryptosporidium and microsporidium from the small intestine, eventually leads to biliary cirrhosis and liver failure, which greatly complicates prognosis. SC should be considered in patients with lymphocyte defects and cholestatic jaundice. All such patients should be warned against drinking unpurified water, and against having close contact with dog pets. When there is a full-blown phenotype of combined immunodeficiency, we can fear the complications of malignancy and bone marrow failure. In contrast, it is unclear what the best approach is with asymptomatic patients carrying a deleterious variant in LIG4. In theory, they will accumulate DNA double-strand breaks and cell damage that result in increased apoptosis of hematopoietic cells, with the consequent risk of late-onset aplastic anemia and malignancy. Felgentreff et al. (5) recently reported immunological findings in two asymptomatic siblings who shared a LIG4 bi-allelic mutation (K449Q/R814X) with their sister (the proband), but not a history of infections; all three siblings with compound heterozygous mutations had: low mean corpuscular volume, B-cell lymphopenia, shortened telomeres, reduced naïve T-cells, and increased radiosensitivity, as well as some skewing of their lymphocytes' receptor repertoires. The immune defects are thus present but clinically silent, and environmental or infectious triggers might precipitate bone marrow failure or myelodysplasia. The differential diagnosis of LIG4 deficiency includes Nijmegen Breakage Syndrome (NBS), RAD50 and NHEJ1 deficiencies; Fanconi anemia, and any other congenital disease presenting with: microcephaly, facial dysmorphisms (described as bird-like facies); hypogammaglobulinemia, and low B-cells; including IKAROS and NFKB2 deficiencies. Dubowitz and Seckel's are clinical syndromes of which LIG4 deficiency patients undoubtedly represent a considerable subset of cases (19). Of note, LIG4 deficient patients may first seek medical care for hematologic malignancies, but respond badly to chemotherapy and radiotherapy; the astute clinician should consider this diagnosis in patients with suggestive clinical features (12), and consider instead hematopoietic stem-cell transplantation (HSCT) after a reduced intensity conditioning (RIC) regime. Not all patients have had microcephaly, but all had radiosensitivity when their cell cultures were exposed to ionizing gamma radiation. Our twin sisters' cells were reported normal or negative for the bleomycin (BLM) radiomimetic test, which has been described to have a strong positive correlation when compared to ionizing radiation with gamma rays. However, it has also been found to be more selective and less predictable than gamma radiation (27–29). BLM is an antibiotic obtained from Streptomyces verticillus, used in the treatment of cancer and considered a radiomimetic for its induction of single and double DNA strand breaks, in the presence of iron ions in cell cultures (27). Given the dreaded fatal complications of hematologic neoplasia, bone marrow failure and chronic liver disease, the best chance LIG4-deficient patients with severe (hematological/immunological) phenotypes have of reaching adulthood, might be to receive an HSCT (11, 30) under the best possible conditions (HLA-identical donor, a reduced intensity conditioning regime with low-dose Cyclosporin A (24, 30, 31), infection-free, no organ failure). The neurological deficits and mental retardations are usually mild enough to allow for a happy and productive life in transplant survivors, capable of loving and being loved, and of learning a craft. In conclusion, LIG4 deficient patients may present soon after birth or later in life, with, or without: a family history of consanguinity and affected siblings, microcephaly, beaked nose, T-B-NK+ SCID, Omenn syndrome, low serum immunoglobulins, and very low B-cells, worsening pancytopenia, radiosensitivity; and they may develop bone marrow failure, sepsis, severe bleeding, and/or hematologic malignancies. Early diagnosis is crucial, as hematologic and infectious complications are more frequent with increasing age, and because RIC HSCT may be curative.

Ethics Statement

The molecular and genetic diagnostic studies were approved by the Institutional Review Board (Comité de Investigación) at the National Institute of Pediatrics. Said studies were preceded by informed consent from the patients' next of kin. Face photographs are included with authorization from their mothers.

Author Contributions

AB coordinated the care of one patient, conceived the manuscript and helped collect data. IC supervised and performed the analysis of exome sequencing for one patient. CA-V supervised and analyzed exome sequencing for one patient, edited the manuscript, and participated in scientific discussions. MY-N coordinated the care of two patients, proposed differential diagnoses and discussed the manuscript. KC-S performed the WES for one of the patients. MG-C coordinated the care of two patients. MP participated in the genetic diagnosis of one patient, and discussed the manuscript. MG performed and analyzed lymphoproliferation assays. EM participated in the molecular and genetic diagnoses of one patient. DM participated in clinical data collection. LF was involved in the genetic diagnosis of one patient and reviewed the manuscript. FE-R facilitated the genetic diagnosis of one patient, and participated in the care of two patients. SE-P participated in the care, and coordinated the molecular and genetic diagnoses of one patient. JO coordinated the genetic diagnosis of one patient. SL conceived and wrote the manuscript, participated in the care of two patients, and built the tables. All the authors read and contributed to the final draft of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Table 2

Key features of published patients with LIG4 deficiency.

PatientMicro-cephalyDysmorphismGrowth failureDevelopmental delayMalignancyInfectionsBone marrow failureReferences
1 (180BR)NoNoNoNoAL LeukemiaNoneNo(6, 7)
2YesReceding forehead, hypertelorism, beaked nose, low set ears, micrognathia, downward palpebral fissures.YesMental retardation, high pitched voice.AM LeukemiaPneumonia (post chemo)Yes (after chemo-therapy)(8)
3 (411BR)YesBird-likeNoYes, globalLymphoma (Diffuse large B-cell, nasopharyngeal)Extensive plantar wartsPancytopenia(4, 9, 10)
4 (2303)YesSeckel-likeYesNoMyelodysplasiaSinusitisPancytopenia(9)
5 (2304)YesSeckel-likeYesNoNoneChronic respiratory infectionsNo(9)
6 (99P0149)YesSeckel-like, Bird-likeYesDevelopmental/mentalNoneSinopulmonary recurrentPancytopenia, hypoplastic marrow(9, 11)
7 (3703)Yes, brachy.NBS-likeNoYes, significant cognitive delayAL LeukemiaNeutropenic sepsis after chemo.Aplasia after chemo.(12)
8 (SC2)NoNoNoNoNoneRecurrent severe respiratory infections, candidiasis in diaper region, chronic diarrheaAnemia, leukopenia(13)
9 (P2)YesNoNoYes, significant neurodevelopmentalNoneLymphopenia(14)
10 (P1)YesNoNoNoBrain and lung non-Hodgkin B cell lymphomaSepsis, diarrheaNeutropenia, lymphopenia, thrombocytopenia(14)
11 (P-1)YesNoYesNoNoneOtitis, bronchiolitis, pneumonia, sepsisLymphopenia(2)
12 (P-2)YesNoNoNoNoneNoneLymphopenia(2)
13YesNoYesNoLymphoma (B-cell, NH) in upper gingiva and hard palatePulmonary aspergillosisProgressive(15)
14YesNoYesYesNoneNoneMarked eosinophilia, mild lymphopenia(16)
15YesLow hairline, prominent nasal bridge, bilateral epicanthiYesNoNoneSinopulmonary, ear.Pancytopenia, progressive(24)
16YesProminent nasal bridge, bilateral epicanthiYesNoNoneNo(24)
17 (F10)YesHypotelorism, small viscerocranium, flat philtrum, thin upper lip, preaxial polydactyly, brachimesophalangy, partial syndactylyYesNeurologic abnormalitiesNoneUrinary tract, sepsisThrombocytopenia(17, 18)
18YesYesNRNoAnal cancerNonePancytopenia(18, 19)
19 (F1.1)YesNoYesYes, mildNoneMild. InfluenzaPancytopenia, self-resolved. Thrombocytopenia(18)
20 (F1.2)YesMalformationsYesYes, mild-moderateNoneMild recurrent (respiratory, skin, GI)Pancytopenia, persistent. Thrombocytopenia(18)
21 (F2)YesMalformationYesYes, mildNoneNonePancytopenia, self-resolved. Thrombocytopenia(18)
22 (F3)YesNoYesYes, mildNoneMild recurrent (respiratory, skin, GI)Thrombocytopenia(18)
23 (F4)YesNoYesNoNoneNoneAnemia, thrombocytopenia(18)
24 (F5)YesNoYesNoNoneNoneLymphopenia(18)
25 (F6)YesMalformationsYesYes, mildNoneMild recurrent (respiratory, skin, GI)Thrombocytopenia(18)
26 (F7)YesNoYesNoNoneNoneThrombocytopenia(18)
27 (F8)YesNoYesYes, mildNoneNoneThrombocytopenia(18)
28 (F9)YesMalformationsYesYes, mildNoneMild recurrent (respiratory, skin, GI)Thrombocytopenia(18)
29 (P2)YesNoYesNoNonePneumonia and sinusitisLymphopenia(5)
30(P1)unknownNoSmall statureNoneWalking pneumoniaMild neutropenia(5)
31 (P3)NoNoNoNoneNoneLymphopenia, mild neutropenia(5)
32NoNoNoNoLymphoma, EBV-pos; diffuse large B-cell; lung and brainEBV stomatitis/encephalitisNo(20)
33 (C1)YesYesYesYes, mildNoneRespiratorySlowly progressive pancytopenia(21)
34 (C2)YesYesYesSevere language delay, moderate mental retardationNoneRespiratory, wartsYes(21)
35YesYesYesYes, mildPneumonia, otitis media, sinusitis, oral candidiasis. UrosepsisPancytopenia(22)
36NoNoNoNoNoneSinopulmonary recurrent, earNo. Progressive lymphopenia(23)
37 LRLNoNoNoNoLung lymphomaPneumonia 3xNoThis report
38 PRLNoNoNoNoBrain B-cell lymphoma (Non-Hodgkin)Pneumonia, Perianal ulcers, SepsisNoThis report
39 FRLNoNoYesNoNoneMild upper respiratory.NoThis report
40 MGPYesYesYesYesNoneRecurrent: sinopulmonary, gastrointestinal, urinaryYesThis report
41 BGPYesYesYesYesNoneRecurrent: sinopulmonary, gastrointestinal, urinaryYesThis report

NR, Not reported.

  30 in total

1.  A patient with mutations in DNA Ligase IV: clinical features and overlap with Nijmegen breakage syndrome.

Authors:  Tawfeg I Ben-Omran; Karen Cerosaletti; Patrick Concannon; Sheila Weitzman; Marjan M Nezarati
Journal:  Am J Med Genet A       Date:  2005-09-01       Impact factor: 2.802

2.  Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient.

Authors:  E Riballo; S E Critchlow; S H Teo; A J Doherty; A Priestley; B Broughton; B Kysela; H Beamish; N Plowman; C F Arlett; A R Lehmann; S P Jackson; P A Jeggo
Journal:  Curr Biol       Date:  1999-07-01       Impact factor: 10.834

3.  Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV.

Authors:  Dietke Buck; Despina Moshous; Régina de Chasseval; Yunmei Ma; Françoise le Deist; Marina Cavazzana-Calvo; Alain Fischer; Jean-Laurent Casanova; Michael R Lieber; Jean-Pierre de Villartay
Journal:  Eur J Immunol       Date:  2006-01       Impact factor: 5.532

4.  A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation.

Authors:  Mirjam van der Burg; Lieneke R van Veelen; Nicole S Verkaik; Wouter W Wiegant; Nico G Hartwig; Barbara H Barendregt; Linda Brugmans; Anja Raams; Nicolaas G J Jaspers; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

5.  DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency.

Authors:  M O'Driscoll; K M Cerosaletti; P M Girard; Y Dai; M Stumm; B Kysela; B Hirsch; A Gennery; S E Palmer; J Seidel; R A Gatti; R Varon; M A Oettinger; H Neitzel; P A Jeggo; P Concannon
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

6.  A severe form of human combined immunodeficiency due to mutations in DNA ligase IV.

Authors:  Anselm Enders; Paul Fisch; Klaus Schwarz; Ulrich Duffner; Ulrich Pannicke; Elisabeth Nikolopoulos; Anke Peters; Marzenna Orlowska-Volk; Detlev Schindler; Wilhelm Friedrich; Barbara Selle; Charlotte Niemeyer; Stephan Ehl
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms.

Authors:  Pierre-Marie Girard; Boris Kysela; Christine J Härer; Aidan J Doherty; Penny A Jeggo
Journal:  Hum Mol Genet       Date:  2004-08-27       Impact factor: 6.150

8.  Comparison of bleomycin and radiation in the G2 assay of chromatid breaks.

Authors:  A D Adema; J Cloos; R H M Verheijen; B J M Braakhuis; P E Bryant
Journal:  Int J Radiat Biol       Date:  2003-08       Impact factor: 2.694

9.  Liver disease in children with primary immunodeficiencies.

Authors:  Fernanda Rodrigues; E Graham Davies; Phillip Harrison; James McLauchlin; John Karani; Bernard Portmann; Alison Jones; Paul Veys; Giorgina Mieli-Vergani; Nedim Hadzić
Journal:  J Pediatr       Date:  2004-09       Impact factor: 4.406

10.  Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure.

Authors:  Bernd Gruhn; Joerg Seidel; Felix Zintl; Raymonda Varon; Holger Tönnies; Heidemarie Neitzel; Astrid Bechtold; Holger Hoehn; Detlev Schindler
Journal:  Orphanet J Rare Dis       Date:  2007-01-15       Impact factor: 4.123

View more
  15 in total

1.  Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor.

Authors:  Fiona Poyer; Raúl Jimenez Heredia; Wolfgang Novak; Petra Zeitlhofer; Karin Nebral; Michael N Dworzak; Oskar A Haas; Kaan Boztug; Leo Kager
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

2.  Critical DNA damaging pathways in tumorigenesis.

Authors:  Jake A Kloeber; Zhenkun Lou
Journal:  Semin Cancer Biol       Date:  2021-04-24       Impact factor: 15.707

Review 3.  Update on DNA-Double Strand Break Repair Defects in Combined Primary Immunodeficiency.

Authors:  Mary A Slatter; Andrew R Gennery
Journal:  Curr Allergy Asthma Rep       Date:  2020-07-09       Impact factor: 4.806

4.  LIG4 syndrome: clinical and molecular characterization in a Chinese cohort.

Authors:  Bijun Sun; Qiuyu Chen; Ying Wang; Danru Liu; Jia Hou; Wenjie Wang; Wenjing Ying; Xiaoying Hui; Qinhua Zhou; Jinqiao Sun; Xiaochuan Wang
Journal:  Orphanet J Rare Dis       Date:  2020-05-29       Impact factor: 4.123

5.  Clinical, Immunological, and Molecular Features of Typical and Atypical Severe Combined Immunodeficiency: Report of the Italian Primary Immunodeficiency Network.

Authors:  Emilia Cirillo; Caterina Cancrini; Chiara Azzari; Silvana Martino; Baldassarre Martire; Andrea Pession; Alberto Tommasini; Samuele Naviglio; Andrea Finocchi; Rita Consolini; Paolo Pierani; Irene D'Alba; Maria Caterina Putti; Antonio Marzollo; Giuliana Giardino; Rosaria Prencipe; Federica Esposito; Fiorentino Grasso; Alessia Scarselli; Gigliola Di Matteo; Enrico Attardi; Silvia Ricci; Davide Montin; Fernando Specchia; Federica Barzaghi; Maria Pia Cicalese; Giuseppe Quaremba; Vassilios Lougaris; Silvia Giliani; Franco Locatelli; Paolo Rossi; Alessandro Aiuti; Raffaele Badolato; Alessandro Plebani; Claudio Pignata
Journal:  Front Immunol       Date:  2019-08-13       Impact factor: 7.561

6.  Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature.

Authors:  Sarah Schober; Karin Schilbach; Michaela Doering; Karin M Cabanillas Stanchi; Ursula Holzer; Patrick Kasteleiner; Jens Schittenhelm; Juergen F Schaefer; Ingo Mueller; Peter Lang; Rupert Handgretinger
Journal:  BMC Pediatr       Date:  2019-10-11       Impact factor: 2.125

Review 7.  Monogenic Adult-Onset Inborn Errors of Immunity.

Authors:  Frederik Staels; Tom Collignon; Albrecht Betrains; Margaux Gerbaux; Mathijs Willemsen; Stephanie Humblet-Baron; Adrian Liston; Steven Vanderschueren; Rik Schrijvers
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

8.  Differential DNA Damage Response of Peripheral Blood Lymphocyte Populations.

Authors:  Kerstin Felgentreff; Catharina Schuetz; Ulrich Baumann; Christian Klemann; Dorothee Viemann; Simona Ursu; Eva-Maria Jacobsen; Klaus-Michael Debatin; Ansgar Schulz; Manfred Hoenig; Klaus Schwarz
Journal:  Front Immunol       Date:  2021-09-14       Impact factor: 7.561

Review 9.  Diabetes, Oxidative Stress, and DNA Damage Modulate Cranial Neural Crest Cell Development and the Phenotype Variability of Craniofacial Disorders.

Authors:  Sharien Fitriasari; Paul A Trainor
Journal:  Front Cell Dev Biol       Date:  2021-05-20

Review 10.  DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns.

Authors:  Richa Sharma; Sara Lewis; Marcin W Wlodarski
Journal:  Front Pediatr       Date:  2020-10-23       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.